Cigna (CI) insider buying and selling
Every Table I transaction reported by directors and officers of S&P 500 companies on SEC Form 4 filings (2 business days to file): each row labeled with its official transaction code, nothing filtered out beforehand.
Open-market purchases (code P) are the rare signal, in green; sales (code S) are common and often pre-scheduled (10b5-1). Table II (derivatives) is not included: its prices are exercise prices, not market values. Guide: insider buying.
| Date | Ticker | Insider | Role | Shares | Price | Amount | % of stake | Type / filing |
|---|
Download these transactions as CSV No account, no sign-up. The data is public: it comes from SEC Form 4 filings.
The Cigna Group (CI) insider buying and selling: 1 purchase, 8 sales
43 Form 4 Table I transactions filed with the SEC by The Cigna Group insiders between 2025-09-03 and 2026-09-08 (15-month history): 1 open-market purchase and 8 sales, plus 34 transactions under other Form 4 codes, broken down one by one below. The largest open-market trade is a sale of $59.1M by Cordani David on 2026-05-12.
Cigna insider buying and selling over the last 12 months
Between Oct 21, 2025 and Oct 20, 2026, Cigna insiders filed 1 purchase worth $1.0M and 7 sales worth $66.8M on the open market. The net balance is on the sell side: $65.8M more sold than bought.
The biggest buyer was Cordani David (Chairman & CEO): $1.0M in 1 purchase, the only buyer. The biggest seller was Cordani David (Chairman & CEO): $59.1M in 1 sale, out of 4 different sellers.
The largest trade of the period was a sale of $59.1M on May 12, 2026, by Cordani David (Chairman & CEO), under a 10b5-1 plan. Form 4 on sec.gov (0001739940-26-000044).
Of the 7 sales, 6 (86%, $66.6M) carry the 10b5-1 plan flag on the Form 4, meaning they were scheduled months ahead; the other one does not.
The last three months show 0 purchases and 3 sales, against 0 and 2 in the three before. The latest purchase is from Nov 3, 2025; the latest sale from Sep 3, 2026.
Against its sector (Healthcare, 59 companies with an insider page on this site), over the same dates the median is 9 sales and 0 purchases on the open market. Cigna has more sales than 25 of the other 58, ranks 13 of 59 by net dollars sold, and 19 of the 59 have at least one purchase, Cigna included.
The 20 most important trades
The only open-market purchase first, then the rest, each type from largest to smallest. The full history is in the tool above, already searched.
See all 43 CI trades in the full history →
| Trade date | Filed | Insider | Role | Amount | Code | Filing |
|---|---|---|---|---|---|---|
| 2025-11-03 | 2025-11-03 | Cordani David | Chairman & CEO | $1.0M | P — Open-market purchase Indirect holding, through: By Trust Form 4 footnoteF1 Represents the weighted average price of the shares purchased. The prices actually paid ranged from $241.876 to $241.97 per share. The reporting person will provide to the issuer, any security holder of the issuer, or the Securities and Exchange Commission, upon request, information regarding the number of shares purchased at each price within the range. | SEC |
| 2026-05-12 | 2026-05-14 | Cordani David | Chairman & CEO | $59.1M | S — Open-market sale (scheduled 10b5-1)14 Form 4 footnotesF1 These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 6, 2026. F2 Represents the weighted average price of the shares sold. The prices actually received ranged from $286.43 to $287.425 per share. The reporting person will provide to the issuer, any security holder of the issuer, or the Securities and Exchange Commission, upon request, information regarding the number of shares sold at each price within the range. F3 Represents the weighted average price of the shares sold. The prices actually received ranged from $287.43 to $288.42 per share. The reporting person will provide to the issuer, any security holder of the issuer, or the Securities and Exchange Commission, upon request, information regarding the number of shares sold at each price within the range. F4 Represents the weighted average price of the shares sold. The prices actually received ranged from $288.435 to $289.41 per share. The reporting person will provide to the issuer, any security holder of the issuer, or the Securities and Exchange Commission, upon request, information regarding the number of shares sold at each price within the range. F5 Represents the weighted average price of the shares sold. The prices actually received ranged from $289.435 to $290.43 per share. The reporting person will provide to the issuer, any security holder of the issuer, or the Securities and Exchange Commission, upon request, information regarding the number of shares sold at each price within the range. F6 Represents the weighted average price of the shares sold. The prices actually received ranged from $290.44 to $291.438 per share. The reporting person will provide to the issuer, any security holder of the issuer, or the Securities and Exchange Commission, upon request, information regarding the number of shares sold at each price within the range. F7 Represents the weighted average price of the shares sold. The prices actually received ranged from $291.44 to $292.435 per share. The reporting person will provide to the issuer, any security holder of the issuer, or the Securities and Exchange Commission, upon request, information regarding the number of shares sold at each price within the range. F8 Represents the weighted average price of the shares sold. The prices actually received ranged from $292.44 to $293.435 per share. The reporting person will provide to the issuer, any security holder of the issuer, or the Securities and Exchange Commission, upon request, information regarding the number of shares sold at each price within the range. F9 Represents the weighted average price of the shares sold. The prices actually received ranged from $293.46 to $294.45 per share. The reporting person will provide to the issuer, any security holder of the issuer, or the Securities and Exchange Commission, upon request, information regarding the number of shares sold at each price within the range. F10 Represents the weighted average price of the shares sold. The prices actually received ranged from $294.46 to $295.453 per share. The reporting person will provide to the issuer, any security holder of the issuer, or the Securities and Exchange Commission, upon request, information regarding the number of shares sold at each price within the range. F11 Represents the weighted average price of the shares sold. The prices actually received ranged from $295.46 to $296.45 per share. The reporting person will provide to the issuer, any security holder of the issuer, or the Securities and Exchange Commission, upon request, information regarding the number of shares sold at each price within the range. F12 Represents the weighted average price of the shares sold. The prices actually received ranged from $296.46 to $297.45 per share. The reporting person will provide to the issuer, any security holder of the issuer, or the Securities and Exchange Commission, upon request, information regarding the number of shares sold at each price within the range. F13 Represents the weighted average price of the shares sold. The prices actually received ranged from $297.492 to $298.49 per share. The reporting person will provide to the issuer, any security holder of the issuer, or the Securities and Exchange Commission, upon request, information regarding the number of shares sold at each price within the range. F14 Represents the weighted average price of the shares sold. The prices actually received ranged from $298.495 to $298.675 per share. The reporting person will provide to the issuer, any security holder of the issuer, or the Securities and Exchange Commission, upon request, information regarding the number of shares sold at each price within the range. | SEC |
| 2026-08-04 | 2026-08-06 | Jones Nicole S | See Remarks | $5.4M | S — Open-market sale (scheduled 10b5-1)Form 4 footnoteF1 These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 4, 2026. | SEC |
| 2025-10-03 | 2025-10-07 | Evanko Brian C | See Remarks | $1.6M | S — Open-market sale (scheduled 10b5-1)Form 4 footnoteF1 These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 7, 2025. | SEC |
| 2026-08-18 | 2026-08-20 | Jones Nicole S | See Remarks | $749k | S — Open-market sale (scheduled 10b5-1)Form 4 footnoteF1 This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 4, 2026. | SEC |
| 2026-03-02 | 2026-03-03 | Jones Nicole S | See Remarks | $667k | S — Open-market sale (scheduled 10b5-1)Form 4 footnoteF5 This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 8, 2025. | SEC |
| 2026-03-02 | 2026-03-03 | Neville Everett | See Remarks | $497k | S — Open-market sale (scheduled 10b5-1)Form 4 footnoteF5 This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 22, 2025. | SEC |
| 2026-06-12 | 2026-06-16 | Kates Jamie G | Chief Accounting Officer | $268k | S — Open-market sale | SEC |
| 2026-09-03 | 2026-09-08 | Neville Everett | See Remarks | $175k | S — Open-market sale (scheduled 10b5-1)Form 4 footnoteF1 This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 2, 2026. | SEC |
| 2026-05-12 | 2026-05-14 | Cordani David | Chairman & CEO | $32.3M | M — Option exercise (scheduled 10b5-1)Form 4 footnoteF1 These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 6, 2026. | SEC |
| 2026-02-27 | 2026-03-03 | Cordani David | Chairman & CEO | $4.4M | F — Tax withholding (shares surrendered for taxes)2 Form 4 footnotesF3 Represents shares withheld to satisfy tax obligations upon settlement of strategic performance shares. F4 Represents shares withheld to satisfy tax obligations upon vesting of restricted shares. | SEC |
| 2026-05-13 | 2026-05-14 | Cordani David | Chairman & CEO | $3.9M | M — Option exercise (scheduled 10b5-1)Form 4 footnoteF1 These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 6, 2026. | SEC |
| 2026-08-04 | 2026-08-06 | Jones Nicole S | See Remarks | $2.7M | M — Option exercise (scheduled 10b5-1)Form 4 footnoteF1 These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 4, 2026. | SEC |
| 2026-02-27 | 2026-03-03 | Evanko Brian C | See Remarks | $1.4M | F — Tax withholding (shares surrendered for taxes)2 Form 4 footnotesF3 Represents shares withheld to satisfy tax obligations upon settlement of strategic performance shares. F4 Represents shares withheld to satisfy tax obligations upon vesting of restricted shares. | SEC |
| 2026-02-27 | 2026-03-03 | Jones Nicole S | See Remarks | $787k | F — Tax withholding (shares surrendered for taxes) (scheduled 10b5-1)2 Form 4 footnotesF3 Represents shares withheld to satisfy tax obligations upon settlement of strategic performance shares. F4 Represents shares withheld to satisfy tax obligations upon vesting of restricted shares. | SEC |
| 2025-10-03 | 2025-10-07 | Evanko Brian C | See Remarks | $747k | M — Option exercise (scheduled 10b5-1)Form 4 footnoteF1 These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 7, 2025. | SEC |
| 2026-02-27 | 2026-03-03 | Neville Everett | See Remarks | $403k | F — Tax withholding (shares surrendered for taxes) (scheduled 10b5-1)2 Form 4 footnotesF3 Represents shares withheld to satisfy tax obligations upon settlement of strategic performance shares. F4 Represents shares withheld to satisfy tax obligations upon vesting of restricted shares. | SEC |
| 2026-08-05 | 2026-08-06 | Jones Nicole S | See Remarks | $250k | M — Option exercise (scheduled 10b5-1)Form 4 footnoteF1 These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 4, 2026. | SEC |
| 2026-06-01 | 2026-06-03 | Koka Durga Prasad | EVP, Global CIO | $201k | F — Tax withholding (shares surrendered for taxes)Form 4 footnoteF1 Represents shares withheld to satisfy tax obligations upon vesting of restricted shares. | SEC |
| 2026-06-12 | 2026-06-16 | Kates Jamie G | Chief Accounting Officer | $137k | M — Option exercise | SEC |
The period balance: money in, money out
Across the Form 4 filings submitted between Sep 3, 2025 and Sep 8, 2026, The Cigna Group open-market activity adds up to 1 purchase worth $1.0M and 8 sales worth $68.4M. The net balance is $67.4M on the sell side.
Only codes P and S count, where an insider puts in or takes out their own money. A selling balance like The Cigna Group's is the norm in the S&P 500, where much of the pay comes as stock. It is not a recommendation to buy or sell: it is what was filed.
Every transaction, code by code
| Code | What it means | Trades | Reported amount |
|---|---|---|---|
| A | Grant or award | 18 | $0 |
| F | Tax withholding (shares surrendered for taxes) | 9 | $7.5M |
| S | Open-market sale | 8 | $68.4M |
| M | Option exercise | 7 | $40.2M |
| P | Open-market purchase | 1 | $1.0M |
| Total | Everything filed in the period | 43 | $117.1M |
18 of the 43 rows carry no usable amount on the Form 4: they count as trades and add $0. The code labels come from the SEC index.
Who has traded
Over the 15 months of history, 18 distinct people or entities have filed The Cigna Group transactions: 1 bought on the open market and 5 sold. Counted by CIK, the fixed number the SEC gives each filer, and not by name, which each filer types their own way.
| Filer | Role | Transactions | Bought (count) | Sold (count) | Last filed |
|---|---|---|---|---|---|
| Cordani David | Chairman & CEO | 6 | $1.0M (1) | $59.1M (1) | 2026-05-14 |
| Jones Nicole S | See Remarks | 7 | — | $6.8M (3) | 2026-08-20 |
| Evanko Brian C | See Remarks | 6 | — | $1.6M (1) | 2026-09-03 |
| Neville Everett | See Remarks | 4 | — | $672k (2) | 2026-09-08 |
| Kates Jamie G | Chief Accounting Officer | 4 | — | $268k (1) | 2026-06-16 |
| Koka Durga Prasad | EVP, Global CIO | 3 | — | — | 2026-06-03 |
| Dennison Ann M | EVP, CFO | 2 | — | — | 2026-03-03 |
| Brailer David J | EVP & Chief Health Officer | 1 | — | — | 2025-09-03 |
Shown here are the 8 who moved the most money, out of 18. The rest are in the full history, one link above. The name links to all their trades, in any company. "Transactions" counts any code; the money, open market only. Role: from their latest filing.
Month by month
By the month the trade was executed, not the month it was filed; months with no trades show zero. The busiest month was Mar 2026: 0 purchases and 2 sales, worth $1.2M. 8 of the 15 months have none.
| Month | Purchases | Amount | Sales | Amount |
|---|---|---|---|---|
| Aug 2025 | 0 | $0 | 0 | $0 |
| Sep 2025 | 0 | $0 | 0 | $0 |
| Oct 2025 | 0 | $0 | 1 | $1.6M |
| Nov 2025 | 1 | $1.0M | 0 | $0 |
| Dec 2025 | 0 | $0 | 0 | $0 |
| Jan 2026 | 0 | $0 | 0 | $0 |
| Feb 2026 | 0 | $0 | 0 | $0 |
| Mar 2026 | 0 | $0 | 2 | $1.2M |
| Apr 2026 | 0 | $0 | 0 | $0 |
| May 2026 | 0 | $0 | 1 | $59.1M |
| Jun 2026 | 0 | $0 | 1 | $268k |
| Jul 2026 | 0 | $0 | 0 | $0 |
| Aug 2026 | 0 | $0 | 2 | $6.1M |
| Sep 2026 | 0 | $0 | 1 | $175k |
| Oct 2026 | 0 | $0 | 0 | $0 |
The last month may be partial: a Form 4 is filed up to two business days later. The table does not say whether the pattern is good or bad; it says when it happened.
The Cigna Group (CI) analysis page →
Other Healthcare companies with insider trades
All 500 are listed in the section index →
Which insiders are buying their own company stock →
How to read this data
7 of the 8 sales in the table are flagged as scheduled (10b5-1 plan): signed months ahead and executed automatically, so they say nothing about what the insider thinks today. Cigna's single open-market purchase (code P) is the rare signal: insiders are already paid in stock, so buying more means putting in their own money. The latest filing is from Sep 8, 2026, and a Form 4 arrives up to two business days after the trade.
18 of the 20 rows in the table carry footnotes from the Form 4 itself, folded into the code column and copied verbatim; a row with no footnote means the filing has none.
Guide: Insider buying · all guides
What is behind these trades
The concepts on this page, explained from scratch in the Academy. Free, no account.
- What the efficiency hypothesis says and what it does NOT sayIf an insider's purchase is public and anyone can read it, is there any information left in it? That is the exact question that brings people here.
- Who really moves the market: the types of investorWho sits on the other side of each order, and where a company's own insiders fit among them.
- Supply, demand and price: why it rises and falls constantlyHow a piece of news ends up inside the price, and why the reaction to a filed sale is rarely the one you would expect.
Source: SEC EDGAR Form 4. This is a list of public facts, not financial advice or a recommendation to buy or sell.